• Secondary prophylaxis of visceral leishmaniasis relapses in HIV co-infected patients using pentamidine as a prophylactic agent: a prospective cohort study

      Diro, Ermias; Griensven, Johan van; Woldegebreal, Teklu; Belew, Zewdu; Taye, Melese; Yifru, Sisay; Davidson, Robert N.; Balasegaram, Manica; Lynen, Lut; Boelaert, Marleen; et al. (2018-07)
      2.1 OBJECTIVES 2.1.1 General objective: To document the effectiveness, safety and feasibility of monthly PM secondary prophylaxis (PSP) in VL/HIV co-infected patients that have documented parasite clearance after VL treatment when used for prevention of VL relapse. 2.1.2 Specific objectives of the primary study period Primary objectives In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the effectiveness of PSP in terms of preventing relapse and death; - to assess the safety of PSP in terms of drug-related serious adverse events or permanent drug discontinuations due to adverse events; - to assess the feasibility of PSP in terms of number of patients compliant to therapy during the first year of monthly PM secondary prophylaxis. Secondary objectives; In VL/HIV co-infected patients that have documented parasite clearance after VL treatment: - to assess the safety of PSP in terms of: - drug-related non-serious adverse events - serious adverse events (drug-related or not) - to assess the feasibility of PSP in terms of: - number of treatment interruptions/discontinuations, - number of therapeutic interventions needed to treat adverse drug reactions
    • Seroprevalence of SARS-CoV-2 antibodies among people experiencing homelessness

      Roederer, T; Fourrey, E; Mollo, B; Vanhomwegen, J; Simons, E; Torre, C; Vincent, C; Llosa, A; Luquero, F (2020-05)
    • Severe acute malnutrition and retrospective all-cause mortality in children under 5 years of age in target areas of Zamfara State, Nigeria: a SMART survey.

      Hadera, Amdom; Huisman, Geke; Kaur, Gurpreet; Oluyide, Bukola; Greig, Jane E.; Bil, Karla; Roggeveen, Harriet; van der Kam, Saskia; MSF-OCA (2018-07)
      2. OBJECTIVES 2.1. PRIMARY OBJECTIVES To estimate the all-cause mortality rate and proportion of SAM in children under 5 years of age in target areas in Zamfara State. 2.2. SECONDARY OBJECTIVES  To determine causes of death  To assess morbidity  To assess health seeking behaviour  To assess food security and nutritional practices  Estimate the prevalence of gingivitis in children <5 years of age

      de Wit, Marit; Rao, Bhargavi; Lassovski, Maryvonne; Ouabo, Adelaide; Badjo, Colette; Bousema, Teun; Roper, Cally; Okell, Lucy; Piriou, Erwan; Cibinda; et al. (2018-07)
      Primary Objective: To measure the prevalence of molecular markers of SP resistant malaria in North and South Kivu, DRC. Sulfadoxine/pyrimethamine (SP) forms the backbone of most malaria chemoprevention programmes in high endemicity settings, including intermittent preventative therapy in pregnancy and infants (IPTp and IPTi respectively) as well as seasonal malaria chemoprevention (SMC). P. falciparum parasite resistance to SP threatens recent triumphs preventing malaria infection in the most vulnerable risk groups. WHO guidance is that chemoprevention using SP may not be implemented when prevalence of the dhps K540E gene denoting SP resistance are greater than 50%. Simple, robust polymerase chain reaction (PCR) - based methods for molecular surveillance of resistance to SP have the potential to indicate whether SP-based chemoprevention programmes would be effective in areas where surveillance was conducted, but also to identify early stages of emerging resistance in order to advocate for alternative chemoprevention strategies.A minimum of 750 samples will be collected per province. Three sites per province will provide 250 samples assuming an estimated prevalence of 50% prevalence of dhps K540E gene with 95% confidence and 5% precision. This is also sufficient for robust estimation of the prevalence of dhps 581, an alternative critical marker. This sample size is calculated to estimate regional prevalence, i.e. for both South Kivu and North Kivu, and hence this study requires samples from multiple MSF sites (including from different MSF Operating Centre missions) e.g. Baraka, Kimbi and Lulingu amongst others in South Kivu and Mweso, Rutsuru and Walikale in North Kivu with a minimum total of 750 per province. If estimating specific prevalence in only one limited site, a large sample size would be required.
    • Understanding the health status and humanitarian impact of the recent events in the internally displaced population (IDPs) in Tal Abyad and Manbij districts, northern Syria, 2017

      Malaeb, Rami; Lenglet, Annick; Langlois, Celine; White, Kate; Hussein, Shajib; de Boever, Rieneke; Onus, Robert; Desoulieres, Sophie; MSF-OCA (2018-07)
      Aims and objectives 2.1. Primary objective To estimate the prevalence of current illnesses (self-reported), vaccination coverage, and mental health distress related symptoms in the IDP population in order to obtain a baseline that can guide MSF response activities in Raqqa as well as in Tal Abyad and Manbij districts. 2.2. Secondary objectives 1) To estimate the vaccination coverage for key vaccine preventable diseases in children aged 6-59 months among the new IDP population; 2) To describe the demographic characteristics of the IDP population; 3) To describe the displacement routes and experiences of the IDP population; 4) To estimate the prevalence of self-reported morbidities in the previous two weeks; 5) To estimate the global acute malnutrition (GAM) rate of in children aged 6-59 months and pregnant women; 6) To estimate the prevalence of self-reported major chronic diseases; 7) To estimate the prevalence of symptoms commonly associated with mental health distress; 8) To estimate the prevalence of conflict-related violence/trauma experienced during the recall period (365 days); 9) To estimate the retrospective mortality since the beginning of Ar-Raqqa offensive in northern Syria (12 June 2016); 10) To gain more understanding related to the concerns, challenges and priority needs of the IDPs in the community.
    • Utilization and acceptance of services for survivors of Sexual and Gender-Based Violence: Knowledge, Attitudes, Practices and Perceptions (KAP) in MSF catchment areas in Port-au-Prince, Haiti

      Verputten, Meggy; Siddiqui, Ruby; Gray, Nell; Casimir, Carl-Frederic; Finaldi, Pasquale; Tolboom, Bianca; Lekkerkerker, Michiel; Lokuge, Kamalini; Stringer, Beverly; Ariti, Cono; et al. (2018-07)
      2 Research question and objectives 2.1 Research question To identify factors that could improve SGBV service utilisation and acceptance amongst MSF’s catchment population in Port-au-Prince, Haiti 2.2 Primary objective To understand how to improve utilization of SGBV services for the population in MSF catchment area Port-au-Prince, Haiti 2.3 Specific objectives 1. To understand community knowledge related to SGBV, including its causes, consequences, treatment and services 2. To understand attitudes towards SGBV 3. To explore practices related to SGBV care seeking pathways, including barriers and enablers affecting service access and uptake 4. To understand which strategies/activities people consider would be effective in improving uptake of SGBV services 5. To understand which strategies/activities people consider would be effective in preventing SGBV
    • Vaccination coverage survey for diphtheria, Streptococcus pneumoniae, polio and tetanus in Rohingya refugee settlements in Ukhiya and Teknaf Upazilas, Cox’s Bazar, Bangladesh

      Pereboom, Monique; White, Kate; Van Leeuwen, Crystal; Siddiqui, Ruby; Guzek, John; Sangma, Mitchell; MSF-OCA (2018-07)
      OBJECTIVES PRIMARY OBJECTIVES a) To describe the vaccine coverage (penta / dT) in children aged 6 months to 14 years for diphtheria in the Rohingya Settlement Camps; SECONDARY OBJECTIVES To describe the vaccine coverage of pentavalent, bOPV and PCV vaccines in children aged 6 weeks to 6 years of age in the Rohingya Settlement Camps; To describe the vaccine coverage for diphtheria and tetanus vaccination among 7 - 14 year olds to assess vaccination rates in this age-group in the Rohingya Settlement Camps